Status:

COMPLETED

Narcolepsy Protect Against Alzheimer's Disease?

Lead Sponsor:

University Hospital, Montpellier

Conditions:

Narcolepsy

Amyloid Pathology

Eligibility:

All Genders

65-85 years

Phase:

NA

Brief Summary

Links between orexin and amyloid processes have been underlined recently. During the Alzheimer's process an upregulation of the orexin mechanism has been observed. The pathophysiological mechanism of ...

Detailed Description

The lack of innovative treatments in Alzheimer' disease (AD) is due to the non-understanding of the pathological process. The investigators need to include the latest concept of the sleep-wake/circadi...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Narcolepsy group:
  • Patients with narcolepsy type 1 older than 65 y.o. with orexin deficiency as required by international diagnosis criteria (ICSD3) with a follow-up in the national reference center for narcolepsy;
  • Treated or not with psychostimulant drugs in relation to disease symptoms;
  • Patients with CSF samples available or with scheduled lumbar puncture for diagnosis purpose;
  • No contra-indications of the PET-scan18F-AV-45
  • With a free and informed consent to participate to the study.
  • Control group:
  • Subjects already included in the MEMENTO-AMYging and/or MAPT-AV45 ancillary studies in the memory center with normal cognitive tests after neuropsychological assessments especially in the episodic memory tests and the brain amyloid PET-scan18F-AV-45 data with SuVr measurements.
  • Exclusion criteria:
  • Controls subjects or patients without free and informed consent to participate to the study
  • No PET-scan18F-AV-45 data available
  • No CSF samples
  • Pathologies being life-threatening in a short term
  • Patients deprived of freedom by court or administrative order
  • Patients living in institution
  • Major protected by the Law.

Exclusion

    Key Trial Info

    Start Date :

    April 7 2016

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 1 2017

    Estimated Enrollment :

    38 Patients enrolled

    Trial Details

    Trial ID

    NCT03378453

    Start Date

    April 7 2016

    End Date

    November 1 2017

    Last Update

    December 19 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Montpellier University Hospital, Gui de Chauliac

    Montpellier, France, 34295